This suggests that passive immunization with tau antibodies is a viable therapeutic goal and that the CSF degree of p-tau262/356 or on the microtubule binding domain (MTBD) can function a useful biomarker of tau pathology to observe tau therapeutics in medical trials. The variables that identify